Lightspeed Venture Partners

Lightspeed Venture Partners is one of the largest multi-stage firms in the world, with offices in the US, India, China, Europe, Israel, and Southeast Asia, and a portfolio that has produced category leaders including Snap, Affirm, Carta, Rubrik, Mulesoft, and a long list of AI and infrastructure breakouts. The firm is structured as a global partnership with strong regional autonomy, which means the Indian and Chinese practices in particular operate as fully-resourced, decision-making teams rather than as satellites of the US fund. For healthcare and AI founders, Lightspeed has been an active investor across the AI cycle, with partners including Guru Chahal, Arif Janmohamed, Gaurav Gupta, Bejul Somaia, and others having led rounds in AI infrastructure, applications, and selected healthcare-tech companies, and the firm has done healthcare deals selectively, with a preference for software-economics businesses and AI-native applications rather than therapeutics or devices. Healthcare is a smaller slice of the Lightspeed portfolio than enterprise software, fintech, or consumer, but the firm is increasingly active in healthcare AI, particularly in clinical workflow software and revenue cycle automation. Stage focus is seed through growth, with seed and Series A checks in the three-to-fifteen-million range, Series B and growth scaling into the tens and low hundreds, and a separate growth fund that can lead pre-IPO rounds. Geography is US, India, China, Israel, Southeast Asia, and Europe; the firm is one of the few VC partnerships that can credibly lead rounds in any of those geographies with a local, decision-making partner. Founders who should approach Lightspeed are technical founders building enterprise or consumer software with an AI core, healthcare-AI founders whose business looks like enterprise software, and founders in India, Israel, or Southeast Asia who want a global firm with a local lead. The firm is particularly strong for founders whose markets span geographies, since Lightspeed can credibly help with international expansion in a way that most US-only firms cannot. Founders who should look elsewhere are clinical-stage biotech, devices, and services-heavy care delivery, which are not core categories. The entry path that works best is partner-specific outreach with a warm intro from a portfolio CEO; Lightspeed has a large partner roster, and the right partner is the one whose theses and prior bets pattern-match yours. When you pitch, lead with the team and the technical wedge, and be ready for sharp, specific questions about competition and about the path to defensibility, since Lightspeed partners tend to spend significant time on the competitive landscape. Caveats: Lightspeed is large enough that founders should worry about portfolio conflicts in adjacent categories, particularly in AI infrastructure and applications; ask explicitly about competing portfolio companies before going deep; valuations are at market for top-tier rounds; governance includes board seats and meaningful partner involvement, with platform support that is real but not as dense as at GC or a16z.